Watch CBS News

With Buybacks, J&J, Abbott, and Pfizer All See the Same Thing: Cheap Stock

Abbott Labs announced a $5 billion stock buyback plan Monday. Such plans are often used by companies seeking to prop up stock that's down for a good reason, i.e. the company sucks. But in a market like this one, where everyone is down at bizarre lows, suddenly those buybacks look like cash-generating plans.

What makes pharma different from other industries is that many of the larger companies are sitting on assets akin to something you'd see at a bank. Now Abbott is throwing $5 billion at its own stock, which is down from $59-something to $54-something since September. With the market in a funk, the company is betting that it's simply getting a piece of itself on the cheap, and is likely to go up as soon as this credit thing works its way out.

Johnson & Johnson, which has its Q4 earings call Tuesday, has put $6.6 billion into its own stock in the last year.

Pfizer has a similar ongoing plan, worth $5 billion.

There are, of course, companies trying to do the opposite -- pay top dollar for stock in a down market that, on its own, was not worth it. One example, King Pharma, is sticking to its guns with its $37 a share tender offer for AlPharma stock. The stock traded at just under that level after the offer was made but is now down in the $33-something area since the crash. That makes King's extended offer look a lot more juicy -- AlPharma holders are among the few investors right now who can see part of their portfolios go up

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.